Objective: Life expectancy of patients with congenital heart disease has improved over the past decades, increasing the need for a durable pulmonary prosthetic valve. Biological valves in various forms have become the valve of choice for pulmonary valve replacement (PVR), but structural valve deterioration is unavoidable in the long term. Use of a mechanical valve could be an alternative, but data on long-term outcomes are sparse.
Perspective
Literature on the long-term behavior of the different pulmonary prosthetic valves is scarce, especially on mechanical valves. With this study, we highlight the medium-to long-term performance of mechanical valves in the pulmonary position. Our results show a limited risk of valvular thrombosis and promising results for thrombolytic treatment. A mechanical valve can be a valid option for pulmonary valve replacement in selected patients.
See Editorial Commentary page 1379.
See Editorial page 1368.
Pulmonary valve replacement (PVR) is among the most common procedures in patients with right-sided congenital heart disease. 1, 2 No valve prostheses have been designed specifically for the pulmonary position, for which reason aortic valve prostheses (both tissue and mechanical) are usually used in the pulmonary position. Exceptions are jugular venous xenograft valves that are available in a limited size range of 12 to 22 mm diameter and pulmonary allografts (homografts). Aortic tissue prosthetic valves in various models and allografts have been the valves of choice for particularly adult PVR 2 because of a low risk of thrombosis without the need for anticoagulation. However, tissue valves have a limited lifespan caused by structural valve degeneration, 3, 4 which seems to occur earlier in the pulmonary than in the aortic position, rendering reinterventions unavoidable in all but elderly patients.
Mechanical prosthetic valves have been the gold standard for left-sided valve replacement in patients younger than age 60 years and could be a viable alternative to bioprostheses for patients in need of a PVR, particularly for patients with high surgical risk and patients already using anticoagulation agents. However, there are serious concerns about the higher risks of valvular thrombosis in right-sided mechanical valves as well as the bleeding risk resulting from lifelong anticoagulation use.
A recent meta-analysis on mechanical PVR (MPVR) showed an average valvular thrombosis occurrence of 2.2% at an average mean follow-up of 73 months (range, 8-180 months). 5 However, this study was limited by a stark heterogeneity between studies and no time-related analysis was possible. A large study on the long-term functionality of MPVR is missing in the current literature.
The objective of this study was to evaluate medium-to long-term results of MPVR, using a large multicenter database combining updated data from the 7 largest studies worldwide from 2009 to 2015, [6] [7] [8] [9] [10] [11] [12] with a focus on valvular thrombosis as a primary end point. Thrombolysis, reoperation, and death were chosen as secondary end points because death is more associated with cardiac failure than with the prosthetic valve, whereas thrombolysis and reoperation are the result of the primary end point.
METHODS

Study Design
This study was designed as a multicenter retrospective study to observe the long-term functionality of a first MPVR. The primary end point was first valvular thrombosis, whereas secondary end points were thrombolysis, reoperation, and mortality. To minimize patient-related factors (such as thrombophilia), follow-up of second mechanical valves introduced at reoperation were not further analyzed. All corresponding authors of articles with a minimum of 15 mechanical pulmonary valves published between May 2009 and May 2015 [6] [7] [8] [9] [10] [11] [12] agreed to participate in this retrospective chart review study, where the data were to be completed and updated from the time of their original publication. Patients diagnosed with carcinoid heart disease were excluded from the study due to the poor prognosis associated with carcinoid heart disease. Data transfer agreements are in place between all institutions and the University Medical Center Groningen.
Data Collection
All data were de-identified and compiled at the time of collation into the clinical database. Institutional review board approval was obtained by each separate institution before the collection of the data. Applicable legislation in the Netherlands stipulates that retrospective anonymized chart research is not subjected to institutional review board review. Ethics review was not deemed necessary upon question of individual ethics review boards. Data were collected retrospectively, using electronic and paper patient records. No identifiers were linked to patients in this collective database. Centers from the following towns contributed to this study: Barcelona, Spain; Graz, Austria; Groningen, The Netherlands; Munich and L€ ubeck, Germany; Rochester, Minnesota; Seoul, Republic of Korea; and Tehran, Iran. Data were collected and entered by the individual centers in a predetermined data submission file. We used the following parameters:
Patient characteristics: age, gender, original diagnosis, previous surgeries, concomitant medication, and previous pregnancies. Procedural information: prosthetic valve brand, model and labeled size, date of implantation, concomitant procedures, complications, antithrombotic regimen, tricuspid annular plane systolic excursion (TAPSE), left ventricular ejection fraction (LVEF), and postoperative valve flow velocity, determined by continuous wave Doppler echocardiography. Follow-up information: valvular thrombosis, death, cause of death, valve replacement, thrombolysis of valvular thrombosis, date of the last follow-up visit, and pregnancies.
Transthoracic echocardiography was recorded within 1 year postoperatively. Local protocols were followed for obtaining and evaluating the echocardiographic images. Right ventricular systolic dysfunction was defined as TAPSE 16. Moderately impaired left ventricular systolic dysfunction was defined as a LVEF 45% and severe dysfunction as a LVEF < 30%. The variable ''thrombosis'' also includes pannus because the difference is often not obvious.
Labeling of prosthetic heart valves has changed over the years, although not all manufacturers adhere to the applicable International Standards Organization standards. The tissue annulus diameter of the patient is meant to reflect the labeled size. Thus, the labeled size reflects the inner orifice diameter (IOD) in supra-annular valves and the outer diameter in intra-annular valves. To take into account as many aspects as possible, we collected the IOD of all prosthetic valves from the manufacturer's specifications. Thus, IOD was chosen instead of the in vitro determined effective orifice area because of additional inconsistencies in the applicable methods used for measuring the effective orifice area. All data files were merged into 1 database and prepared for analysis at the University Medical Center Groningen. 
Abbreviations and Acronyms
PVR Procedures
Operative procedures and valvular selection were performed according to local standards at the time of surgery. [6] [7] [8] [9] [10] [11] [12] Uniformly, PVR was performed through a median sternotomy with the use of cardiopulmonary bypass. Follow-up visits were scheduled regularly according to local guidelines. International normalized ratio (INR) was targeted between 2.3 and 4.5 for all centers; Table 1 shows target INR levels for the individual centers.
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Thrombolysis
Protocols regarding thrombolysis have changed over time, due to the long period of inclusion and follow-up period of this study. No uniform thrombolysis protocol was present in all inclusion sites except for Munich and Tehran (Appendix E1).
Statistics
Continuous data are presented as means with standard deviations or medians with range, as appropriate. Frequencies are displayed as absolute numbers and percentages. Follow-up time was calculated between the date of PVR and the date of last follow-up, valvular thrombosis, redo-PVR, or death. Survival analyses were performed on a patient level. Competing risk analysis techniques were applied for the end points. Cumulative incidence curves were computed to display the event probabilities during the follow-up. Cox proportional hazard methodology was used to determine univariate and multivariate relationships between the covariates and time to event. Gender, hospital, and age were corrected for in our multivariate model. Most statistical analyses were performed using IBM-SPSS statistics version 22.0 (IBM-SPSS Inc, Armonk, NY). The cumulative incidence graph was generated using STATA version 14.0 (StataCorp LP, College Station, Tex).
RESULTS
We retrospectively collected data on 364 patients who received a first mechanical aortic valve prosthesis in the pulmonary position from 1965 to 2014. The number of patients per center varied from 19 to 119. Patient inclusion time periods varied widely across the different centers ( Figure 1 ). The total number of patient-years was 2047 and there was a total of 35 first thromboses (1.7%/patient-year; 95% confidence interval [CI], 1.2%-2.4%) and 20 reoperations (1.0%/patient-year: 95% CI, 0.6%-1.5%).
Baseline characteristics are shown in Table 2 . Mean age was 27.16 AE 12.2 years at the time of MPVR (range, 1-71 years). Tetralogy of Fallot (ToF) was the primary cardiac diagnosis in 69.8%. In 94.9% (241 out of 254) of ToF cases, a total repair had been done before MPVR. The median number of prior cardiac surgeries was 1 (range, 0-7). In 10 cases, no previous procedures had been performed. Median follow-up was 4.26 years (range, 0-33 years), 152 patients had a follow-up of more than 5 years, and 58 patients had more than 10 years of follow-up. Of the female patients, 11 had been pregnant before the MPVR. Four patients were pregnant whilst having an MPVR. Two patients experienced valvular thrombosis relating to pregnancy.
There (Table 2) . Of all patients, 28% had an LVEF 45% postoperatively ( Table 3) . As anticoagulant, warfarin was used in 64.8% (n ¼ 236), acenocoumarol in 105 (28.8%), and phenprocoumon in 16 (4.4%). One patient was only treated with acetylsalicylic acid and for 6 patients the anticoagulation regimen was unknown either due to immediate reoperation or to early operative mortality.
Valvular Thrombosis
There were 35 of 364 (9.6%) reported cases of first valvular thrombosis. Median time between PVR and first valve thrombosis was 2.9 years (range, 0.3-23.2 years). Cox regression calculated freedom from first thrombosis at 5 years was 91% (95% CI, 87%-94%), at 10 years, 86% (95% CI, 81%-91%), and at 15 years 79% (95% CI, 70%-87%) ( Figure 2 and Table E1 ). No valvular thrombosis occurred for the single patient taking acetylsalicylic acid. There seemed to be a relationship between labeled valve size and occurrence of thrombosis, but when repeating the analysis for the IOD, no relationship was found with valvular thrombosis (hazard ratio, 0.99; 95% CI, 0.76-1.3; P ¼ .936). We did detect a center effect in our study; however, when correcting for center, both as a fixed or random effect, there was no influence on outcome.
Inclusion of gender, age, year of implantation, primary cardiac diagnosis, valve brand, type of anticoagulation, simultaneous valve replacements, and prior surgeries and conduit resulted in no correlation of any variable with valvular thrombosis, both univariate nor multivariate.
In 26 of 35 cases (74.3%) of valvular thrombosis, thrombolysis was performed, as shown in Figure 3 . Thrombolysis was successful in 22 of 26 cases (84.6%). In 4 cases, thrombolysis was unsuccessful and reoperation ensued. In 3 cases, reoperation was later necessary after initial successful thrombolysis (at 0.2, 3.7, and 6.2 years, respectively, after thrombolysis). In 1 case, there were 3 successful thrombolysis procedures. Median follow-up after first thrombolysis was 1.5 years (range, 0-7.6 years).
Reoperations
In 20 of 364 cases (5.5%) the prosthetic valve was replaced; 16 of 20 (80%) reoperations were indicated by valvular thrombosis: 1 patient outgrew the prosthesis, the reason for reoperation in the remainder is unknown. The mean time to valve replacement was 7.6 AE 5.5 years. Freedom from reoperation at 5 years was 97% (95% CI, 94%-99%), 91% at 10 years (95% CI, 85%-95%) and 81% at 15 years (95% CI, 71%-90%). Figure 2 shows the freedom from reoperations over time in a cumulative incidence graph depicting 
Mortality
There were 31 of 364 (8.5%) reported deaths, of which 7 of 31 occurred operatively (22.6%), 15 of 31 (48.4%) were cardiac deaths (right ventricle failure, arrhythmias, or sudden death), and in 9 cases the cause was unknown (29.0%). Mean age at death was 40.3 AE 16.0 years (range, 5.3-75.5 years). Of the cardiac deaths, none were valverelated. There was 1 death due to pulmonary hemorrhage with INR level>7. There were no thrombosis-related deaths reported. Survival post-PVR at 5 years was 95% (95% CI, 92%-97%), 91% at 10 years (95% CI, 85%-95%), and 79% at 15 years (95% CI, 67%-88%) (Figure 2 ).
DISCUSSION
The unique size of this study was only possible by combining data from the 7 participating centers, from which we accumulated 364 patients who had a first MPVR performed from 1965 until 2014. By doing so, we created the largest comprehensive dataset so far on MPVR and we were able to provide the most realistic evaluation of mechanical prosthetic valves in the pulmonary position until now.
Valvular thrombosis has always been the major concern with the use of mechanical valves in the pulmonary position. The rate of thrombosis, despite anticoagulation, has always been reported to be appreciably higher than in the aortic position. We found a relatively linear rate of valvular thrombosis of about 1.7% per patient year. Dunne and colleagues 5 published recently a meta-analysis of 19 studies up until 2013, but regrettably could not perform a detailed time-related analysis on the occurrence of valvular thrombosis, so that study does not provide insight into that crucial observation over time.
Our results confirm a higher incidence of valvular thrombosis for mechanical valves in the pulmonary position compared with the literature on aortic and mitral position; reported thrombosis incidences range between 0% and 0.6% per patient-year. [13] [14] [15] [16] [17] However, we should be careful when comparing different populations, particularly because patients receiving a pulmonary valve in most cases have a more complex medical history and surgical background than have patients receiving aortic and mitral valves and, in addition, usually are much younger. On the other hand, thrombosis of right-sided prosthetic valves may be underdiagnosed because partial and nonobstructive thrombosis as well as minor emboli may remain subclinical for a long time. The higher propensity for thrombus formation in the right ventricle is most likely related to its lower pressures and the mechanism of mechanical valves. Whether or not the incidence of thrombus formation is also larger in tissue prostheses in the right ventricle is unknown.
Thrombolysis was found to be remarkably successful in our cohort, with a success rate of 84.6%. The 2014 American Heart Association/American College of Cardiology guidelines advise fibrinolytic therapy as ''reasonable'' for thrombosed right-sided prosthetic heart valves, 18 which might be changed to ''recommended'' based on our findings. We presume, because we have no evidence, that this might apply to the tricuspid position as well. Nonetheless, we should be aware that information on the complications of thrombolysis is not available and did not surface in the current study. More research is necessary on the longterm effect of thrombolysis on the treatment of valvular thrombosis.
Although we did not find any relevant predictors for valvular thrombosis, several factors could influence its occurrence. Local circumstances and practices could influence the occurrence of valvular thrombosis, most notably the availability of universally adequate antithrombotic services. In addition, the frequency of screening during the early stages after PVR could play a role in detecting and treating early thrombi. Noncompliance with anticoagulation therapy has been shown to play an important role in the incidence of valvular thrombosis. These factors could play an important role in the center effect we detected. Because the objective of this study was to analyze valves instead of centers, we lacked adequate parameters to make a valid analysis between centers.
Reintervention rates (both catheter-based and reoperation) in our study are lower than in the large Nomoto study 19 with 611 biological valves: our MPVR study showed 97% freedom of reoperation only at 5 years postoperatively and 91% at 10 years post-PVR. These observations were not equal for all valve brands. Nomoto reported a Kaplan-Meier estimate of 80% freedom from reintervention at 5 years for the Mitroflow (LivaNova, London, United Kingdom), but 80% at 8 years out for Perimount pericardial valves (Edwards Lifesciences). 19 Studies with similar populations are heterogeneous and provide less information for comparison, but the impression is that their results vary between Nomoto and the work by Babu-Narayan, 20 who reported much better results in a study of 220 patients. Table 4 presents recent relevant literature on biological valves in the pulmonary position. [19] [20] [21] [22] [23] [24] [25] [26] [27] Because younger age has been associated with higher rates of tissue valve degeneration and subsequent replacement, we did not include studies with predominantly young children in Table 4 . Pulmonary homografts were only reported by Van de Woestijne and colleagues, 25 who reported an 83% freedom from homograft replacement at 10 years in an adult ToF population.
Although with biological valves a younger age at implantation is associated with higher rates of valve degeneration, 21 we saw no association between age at implantation and reoperation for mechanical valves. Arguably, tissue valves offer the advantage of not needing anticoagulation, whereas future replacements could be performed by transcatheter valve-in-valve procedures. Although percutaneous procedures are currently fashionable, even medium-term results of these procedures are lacking, yet there is an emergence of articles on an associated elevated endocarditis risk of up to 3% per patient year. [28] [29] [30] Current literature on longer-term results of tissue valve prosthetic performance in the pulmonary position (without valve-invalve procedure) is so heterogeneous as to preclude formal comparison with this study, but mechanical valves seem not to do worse. The obvious advantage of catheter-based tissue valve implantation is that the procedure is far less traumatic and patient recovery is more rapid. Future development of mechanical valve prostheses specifically designed for the right ventricle might even improve upon the current propensity for thrombosis of 1.7% per patient-year and reoperation of 1.0% per patient-year. Finally, a normal pulmonary valve is a larger valve than the aortic valve in each individual because of the lower pressures involved. Thus, there are probably limits to which we should narrow the pulmonary valve with valve-in-valve procedures without inflicting an undue burden on the right ventricle, particularly of young patients and on exercise.
Bleeding complications were not recorded in this study, which arguably constitutes a major limitation. The reason for not recording bleeding complications is the historic nature of the study, and many patient files were incomplete. In addition, many patients are and were not followed-up by cardiologists from the center performing the operation. On the contrary, many received follow-up from remotely located cardiologists and feedback about such complications is vastly incomplete. Because we knew any attempt at collecting data on bleeding would appreciably underestimate the incidence, we decided not to do so. However, because the target INR is usually in the range of mechanical mitral valve prophylaxis, we presumed the bleeding incidences to be in that range.
In our study, a relatively high percentage (70%) of patients with available echocardiogram data appeared to have right ventricle systolic dysfunction 1 year after surgery, as measured by TAPSE. However, one should be careful with use of TAPSE as a parameter in this population particularly because of the high rates of previous surgeries. TAPSE is systematically reduced after cardiac surgery and does not always reflect true right ventricle dysfunction. Longitudinal right ventricle excursion is usually reduced after surgery, but if radial contraction is preserved, the ejection fraction may be normal. 31 This imposes limitations to our interpretation of the echocardiography data available.
Almost no valve-related death was found in our study: there was 1 death due to hemorrhage and none due to thrombosis or reoperation. For 9 patients cause of death was unknown, so it is impossible to comment on the cause of their deaths. All-cause survival was comparable to other pulmonary valve replacement cohorts, with 95% at 5 years and 91% at 10 years. 25 
Limitations
The nonrandomized and retrospective nature of this study including a number of heterogeneous populations are major limitations of this study. In addition, we updated studies that had already been published, so that publication bias undeniably plays a role. Within this population there is substantial variance; for instance, time period of inclusion, underlying cardiac conditions, and number of surgeries, contributing to heterogeneity of this cohort. Bleeding events were not registered in this study due to its historic nature and the likely underreporting inherent to such a study. In addition, local cardiologists remotely located from the center performing the operation followed-up with many patients and communications were not always recorded. Nonetheless, we have no reason to expect a higher incidence of bleeding events compared with mitral valve implantations because this is not related to the valve position but rather to INR control. Where the strength of this study lies is in its global nature. At the same time, a major limitation of the study is heterogeneity. Another limitation is the nonstandard anticoagulation management among institutions and throughout the study period, because anticoagulation control is crucial for the functional integrity of a prosthesis. 32 
CONCLUSIONS
A mechanical valve can be a valid choice for PVR. MPVR is associated with a limited risk of valvular thrombosis, for which thrombolysis was an effective treatment VIDEO 1. Tjark Ebels, MD, PhD, congenital thoracic surgeon at University Medical Center Groningen, explaining the importance and relevance of this work. Video available at: http://www.jtcvsonline.org/article/ S0022-5223(17)31050-4/addons. 33, 34 and patients likely to be noncompliant with anticoagulation therapy (Video 1).
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